Systems Genomics Identifies a Key Role for Hypocretin/Orexin Receptor-2 in Human Heart Failure

Marco V. Perez, Aleksandra Pavlovic, Ching Shang, Matthew T. Wheeler, Clint L. Miller, Jing Liu, Frederick E. Dewey, Stephen Pan, Porama K. Thanaporn, Devin Absher, Jeffrey Brandimarto, Heidi Salisbury, Khin Chan, Rupak Mukherjee, Roda P. Konadhode, Richard M. Myers, Daniel Sedehi, Thomas E. Scammell, Thomas Quertermous, Thomas CappolaEuan A. Ashley

Research output: Contribution to journalArticlepeer-review

27 Scopus citations


Background The genetic determinants of heart failure (HF) and response to medical therapy remain unknown. We hypothesized that identifying genetic variants of HF that associate with response to medical therapy would elucidate the genetic basis of cardiac function. Objectives This study sought to identify genetic variations associated with response to HF therapy. Methods This study compared extremes of response to medical therapy in 866 HF patients using a genome-wide approach that informed the systems-based design of a customized single nucleotide variant array. The effect of genotype on gene expression was measured using allele-specific luciferase reporter assays. Candidate gene transcription-deficient mice underwent echocardiography and treadmill exercise. The ability of the target gene agonist to rescue mice from chemically-induced HF was assessed with echocardiography. Results Of 866 HF patients, 136 had an ejection fraction improvement of 20% attributed to resynchronization (n = 83), revascularization (n = 7), tachycardia resolution (n = 2), alcohol cessation (n = 1), or medications (n = 43). Those with the minor allele for rs7767652, upstream of hypocretin (orexin) receptor-2 (HCRTR2), were less likely to have improved left ventricular function (odds ratio: 0.40 per minor allele; p = 3.29 × 10-5). In a replication cohort of 798 patients, those with a minor allele for rs7767652 had a lower prevalence of ejection fraction >35% (odds ratio: 0.769 per minor allele; p = 0.021). In an HF model, HCRTR2-deficient mice exhibited poorer cardiac function, worse treadmill exercise capacity, and greater myocardial scarring. Orexin, an HCRTR2 agonist, rescued function in this HF mouse model. Conclusions A systems approach identified a novel genetic contribution to human HF and a promising therapeutic agent efficacious in an HF model.

Original languageEnglish (US)
Pages (from-to)2522-2533
Number of pages12
JournalJournal of the American College of Cardiology
Issue number22
StatePublished - 2015


  • HCRTR2
  • Key Words genome-wide association study
  • pharmacogenomics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Systems Genomics Identifies a Key Role for Hypocretin/Orexin Receptor-2 in Human Heart Failure'. Together they form a unique fingerprint.

Cite this